Foamix Pharmaceuticals Ltd. Stock Nasdaq
Equities
IL0011334385
Biotechnology & Medical Research
Financials (USD)
Sales 2024 * | 400K | Sales 2025 * | 250K | Capitalization | 32.69M |
---|---|---|---|---|---|
Net income 2024 * | -32M | Net income 2025 * | -40M | EV / Sales 2024 * | 81.7 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 131 x |
P/E ratio 2024 * |
-2.78
x | P/E ratio 2025 * |
-2.85
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.55% |
Latest transcript on Foamix Pharmaceuticals Ltd.
Managers | Title | Age | Since |
---|---|---|---|
David Domzalski
CEO | Chief Executive Officer | 58 | 20-02-29 |
Tyler Zeronda
DFI | Director of Finance/CFO | 38 | - |
Iain Stuart
CTO | Chief Tech/Sci/R&D Officer | 51 | 20-02-29 |
Members of the board | Title | Age | Since |
---|---|---|---|
Pat LePore
BRD | Director/Board Member | 69 | 20-09-09 |
Steven Basta
BRD | Director/Board Member | 59 | 14-12-31 |
Anthony Bruno
BRD | Director/Board Member | 68 | 20-02-29 |
1st Jan change | Capi. | |
---|---|---|
+20.50% | 127B | |
+24.51% | 117B | |
+25.44% | 27.67B | |
-18.73% | 20.33B | |
-15.17% | 16.79B | |
-16.34% | 15.63B | |
+13.02% | 14.84B | |
-47.10% | 14.65B | |
+56.82% | 14.43B |